

PRODUCERS' QUESTIONNAIRE
ELECTROLYTIC MANGANESE DIOXIDE FROM AUSTRALIA, CHINA, GREECE,
IRELAND, JAPAN, AND SOUTH AFRICA

Return completed questionnaire to:

UNITED STATES INTERNATIONAL TRADE COMMISSION
Office of Investigations, Room 615
500 E Street, SW, Washington, DC 20436

So as to be received by the Commission by no later than August 14, 2003

The information called for in this questionnaire is for use by the United States International Trade Commission in connection with its antidumping investigations concerning electrolytic manganese dioxide ("EMD") from Australia, China, Greece, Ireland, Japan, and South Africa (invs. Nos. 731-TA-1048-1053 (Preliminary)). The information requested in the questionnaire is requested under the authority of the Tariff Act of 1930, title VII. This report is mandatory and failure to reply as directed can result in a subpoena or other order to compel the submission of records or information in your possession (19 U.S.C. § 1333(a)).

Name of firm _____
Address _____
City _____ State _____ Zip code _____
World Wide Web address _____

Has your firm produced EMD (as defined in the instruction booklet) at any time since January 1, 2000?

☐

NO (Sign the certification below and promptly return only this page of the questionnaire to the Commission)

☐

YES (Read the instruction booklet carefully, complete all parts of the questionnaire, sign the certification, and return the entire questionnaire to the Commission)

CERTIFICATION

I certify that the information herein supplied in response to this questionnaire is complete and correct to the best of my knowledge and belief and understand that the information submitted is subject to audit and verification by the Commission.

By signing this certification I also grant consent for the Commission, and its employees and contract personnel, to use the information provided in this questionnaire and throughout these investigations in any other import-injury investigations conducted by the Commission on the same or similar merchandise. (If you do not consent to such use, please note the certification accordingly.)

I acknowledge that information submitted in this questionnaire response and throughout these investigations may be used by the Commission, its employees, and contract personnel who are acting in the capacity of Commission employees, for developing or maintaining the records of these investigations or related proceedings for which this information is submitted, or in internal audits and investigations relating to the programs and operations of the Commission pursuant to 5 U.S.C. Appendix 3. I understand that all contract personnel will sign non-disclosure agreements.

Name and Title of Authorized Official

Date

Signature of Authorized Official

()

Phone

()

Fax

PART I.--GENERAL QUESTIONS

The questions in this questionnaire have been reviewed with market participants to ensure that issues of concern are adequately addressed and that data requests are sufficient, meaningful, and as limited as possible. Public reporting burden for this questionnaire is estimated to average 40 hours per response, including the time for reviewing instructions, searching existing data sources, gathering the data needed, and completing and reviewing the questionnaire. Send comments regarding the accuracy of this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Office of Investigations, U.S. International Trade Commission, 500 E Street, SW, Washington, DC 20436.

- I-1. Please report below the actual number of hours required and the cost to your firm of preparing the reply to this questionnaire and completing the form.

_____ hours _____ dollars

- I-2. Provide the name and address of establishment(s) covered by this questionnaire (see page 3 of the instruction booklet for reporting guidelines). If your firm is publicly traded, please specify the stock exchange and trading symbol.

- I-3. Do you support or oppose the petition? Please explain.

☐ Support ☐ Oppose ☐ Take no position

As indicated at the top of the page, your response to this question will be treated as business proprietary. However, if the Commission's final determinations in the investigations are affirmative and antidumping duty orders are issued, the Commission, pursuant to section 754 of the Tariff Act of 1930, will provide a list of firms supporting the petition to the Customs Service for possible distribution of any antidumping duties that may be collected. If you wish to waive business proprietary treatment of your response to this question in order to make your position with respect to the petition public and allow inclusion of your firm on that list, indicate "yes" below.

☐ Yes ☐ No (that is, I do not wish my position on the petition to be made public)

- I-4. Is your firm owned, in whole or in part, by any other firm?

☐ No ☐ Yes--List the following information.

<u>Firm name</u>	<u>Address</u>	<u>Extent of ownership</u>
_____	_____	_____
_____	_____	_____

PART I.--GENERAL QUESTIONS--Continued

- I-5. Does your firm have any related firms, either domestic or foreign, which are engaged in importing EMD from Australia, China, Greece, Ireland, Japan, or South Africa into the United States or which are engaged in exporting EMD from Australia, China, Greece, Ireland, Japan, or South Africa to the United States?

☐ No ☐ Yes--List the following information.

<u>Firm name</u>	<u>Address</u>	<u>Affiliation</u>
_____	_____	_____
_____	_____	_____

- I-6. Does your firm have any related firms, either domestic or foreign, which are engaged in the production of EMD?

☐ No ☐ Yes--List the following information.

<u>Firm name</u>	<u>Address</u>	<u>Affiliation</u>
_____	_____	_____
_____	_____	_____

PART II.--TRADE AND RELATED INFORMATION

Further information on this part of the questionnaire can be obtained from Christopher J. Cassise (202-708-5408; ccassise@usitc.gov). **Supply all data requested on a calendar-year basis.**

- II-1. Who should be contacted regarding the requested trade and related information?

Company contact: _____
Name and title

Phone No. _____ E-mail address _____

- II-2. Has your firm experienced any plant openings, relocations, expansions, acquisitions, consolidations, closures, or prolonged shutdowns because of strikes or equipment failure; curtailment of production because of shortages of materials; or any other change in the character of your operations or organization relating to the production of EMD since January 1, 2000?

☐ No ☐ Yes--Supply details as to the time, nature, and significance of such changes.

PART II.--TRADE AND RELATED INFORMATION--Continued

II-3. Does your firm produce other products on the same equipment and machinery used in the production of EMD?

☐ No ☐ Yes--List the following information.

Product

Basis for allocation of capacity data

II-4. Please describe the constraint(s) that set the limit(s) on your production capabilities.

II-5. Does your firm produce other products using the same production and related workers employed to produce EMD?

☐ No ☐ Yes--List the following information.

Product

Basis for allocation of employment data

II-6. Since January 1, 2000, has your firm been involved in a toll agreement (see definition in the instruction booklet) regarding the production of EMD?

☐ No ☐ Yes--Name firm: _____

II-7. Does your firm produce EMD in a foreign trade zone (FTZ)?

☐ No ☐ Yes--Identify FTZ(s): _____

II-8. Since January 1, 2000, has your firm imported EMD?

☐ No ☐ Yes--**COMPLETE AND RETURN THE ENCLOSED IMPORTERS' QUESTIONNAIRE**

PART II.--TRADE AND RELATED INFORMATION--Continued

II-9. Report your firm's production capacity, production, shipments, inventories, and employment related to the production of EMD in your U.S. establishment(s) during the specified periods. (See definitions in the instruction booklet.)

(Quantity in short tons, value in \$1,000)					
Item	Calendar years			January-June	
	2000	2001	2002	2002	2003
AVERAGE PRODUCTION CAPACITY (<i>quantity</i>)					
BEGINNING-OF-PERIOD INVENTORIES (<i>quantity</i>)					
PRODUCTION (<i>quantity</i>)					
U.S. SHIPMENTS:					
Commercial shipments:					
<i>Quantity</i> of commercial shipments					
<i>Value</i> of commercial shipments					
Internal consumption:					
<i>Quantity</i> of internal consumption					
<i>Value</i> ¹ of internal consumption					
Transfers to related firms:					
<i>Quantity</i> of transfers to related firms					
<i>Value</i> ¹ of transfers to related firms					
EXPORT SHIPMENTS: ²					
<i>Quantity</i> of export shipments					
<i>Value</i> of export shipments					
END-OF-PERIOD INVENTORIES ³ (<i>quantity</i>)					
U.S. SHIPMENTS TO DISTRIBUTORS (<i>quantity</i>)					
U.S. SHIPMENTS TO END USERS (<i>quantity</i>)					
AVERAGE NUMBER OF PRWs					
HOURS WORKED BY PRWs (<i>1,000 hours</i>)					
WAGES PAID TO PRWs (<i>value</i>)					
¹ Internal consumption and transfers to related firms must be valued at fair market value. In the event that you use a different basis for valuing these transactions, please specify that basis (e.g., cost, cost plus, etc.) and provide value data using that basis for 2000, 2001, and 2002 below:					
² Identify your principal export markets: _____					
³ Reconciliation of data. --Please note that the quantities reported above should reconcile as follows: beginning-of-period inventories, plus production, less total shipments, equals end-of-period inventories. Do the data reported reconcile?					
<input type="checkbox"/> Yes <input type="checkbox"/> No--Please explain: _____					

PART II.--TRADE AND RELATED INFORMATION--Continued

II-10. Report your firm's U.S. shipments of the various "grades" of EMD during the specified periods. Please be advised that these grades are within the definition of EMD and are merely subsets of the EMD within the scope of these investigations. Therefore, the sum of the shipment data of all grades shown in question II-10 should equal total U.S. shipments shown in question II-9.

(Quantity in short tons, value in \$1,000)					
Item	Calendar years			January-June	
	2000	2001	2002	2002	2003
U.S. SHIPMENTS OF ALKALINE GRADE EMD:					
Commercial shipments:					
Quantity of commercial shipments					
Value of commercial shipments					
Internal consumption/transfers to related firms:					
Quantity of internal consumption					
Value ¹ of internal consumption					
U.S. SHIPMENTS OF "HIGH DRAIN" ALKALINE GRADE EMD:					
Commercial shipments:					
Quantity of commercial shipments					
Value of commercial shipments					
Internal consumption/transfers to related firms:					
Quantity of internal consumption					
Value ¹ of internal consumption					
U.S. SHIPMENTS LITHIUM GRADE EMD:					
Commercial shipments:					
Quantity of commercial shipments					
Value of commercial shipments					
Internal consumption/transfers to related firms:					
Quantity of internal consumption					
Value ¹ of internal consumption					
U.S. SHIPMENTS ZINC CHLORIDE GRADE EMD:					
Commercial shipments:					
Quantity of commercial shipments					
Value of commercial shipments					
Internal consumption/transfers to related firms:					
Quantity of internal consumption					
Value ¹ of internal consumption					
TOTAL					

PART II.--TRADE AND RELATED INFORMATION--*Continued*

- II-11. If you reported transfers to related firms in question II-9, please indicate the nature of the relationship between your firm and the related firms (e.g., joint venture, wholly owned subsidiary), whether the transfers were priced at market value or by a non-market formula, whether your firm retained marketing rights to all transfers, and whether the related firms also processed inputs from sources other than your firm.
-
-

- II-12. Does your firm produce EMD using titanium anodes, carbon anodes and/or another method of production?

☐ Titanium ☐ Carbon ☐ Other _____

- II-13. Other than direct imports, has your firm otherwise purchased EMD since January 1, 2000? (See definitions in the instruction booklet.)

☐ No ☐ Yes--Report such purchases below for the specified periods.¹

PART II.--TRADE AND RELATED INFORMATION--Continued

(Quantity in short tons, value in \$1,000)					
Item	Calendar years			January-June	
	2000	2001	2002	2002	2003
PURCHASES FROM U.S. IMPORTERS² OF PRODUCT FROM--					
AUSTRALIA:					
Quantity					
Value					
CHINA:					
Quantity					
Value					
GREECE:					
Quantity					
Value					
IRELAND:					
Quantity					
Value					
JAPAN:					
Quantity					
Value					
SOUTH AFRICA:					
Quantity					
Value					
ALL OTHER COUNTRIES:					
Quantity					
Value					
PURCHASES FROM DOMESTIC PRODUCERS:²					
Quantity					
Value					
PURCHASES FROM OTHER SOURCES:²					
Quantity					
Value					
¹ Please indicate your reasons for purchasing this product. If your reasons differ by source, please elaborate.					
² Please list the name of the firm(s) from which you purchased this product. If your suppliers differ by source, please identify the source for each listed supplier.					

PART III.--FINANCIAL INFORMATION

Address questions on this part of the questionnaire to Chand Mehta (202-205-3174).

III-1. Who should be contacted regarding the requested financial information?

Company contact: _____
Name and title

Phone No.

E-mail address

III-2. When does your fiscal year end (month and day)? _____

If your fiscal year changed during the periods for which data are being reported, explain below:

III-3. Accounting basis.--The financial records of your firm are prepared on the basis of:

☐ GAAP ☐ Tax ☐ Cash ☐ Other (specify) _____

III-4. Reports and statements.--Did your firm or your parent prepare any of the statements or documents listed below during the period of the investigation? If so, please submit copies of them along with your completed questionnaire unless they are available on the World Wide Web (including the Securities and Exchange Commission's EDGAR site).

My firm or parent does ____ or does not ____ prepare financial statements (annual reports, 10-K's). Are the above documents available on the World Wide Web?

	YES	NO
At the SEC's EDGAR site?		
At some other site? (WWW address _____)		

My firm or parent does ____ or does not ____ prepare internal profit-and-loss reports on EMD operations which indicate the cost of production of EMD.

My firm or parent does ____ or does not ____ prepare internal reports indicating the cost of production of EMD.

III-5. Other products.--Please list any other products you produced in the facilities in which you produced EMD, and provide the share of net sales accounted for by these other products in your most recent fiscal year:

Product(s)

Share of sales

PART III.--FINANCIAL INFORMATION--Continued

- III-6. **Operations on EMD.**--Report the revenue and related cost information requested below on the EMD operations of your U.S. establishment(s).¹ Note that internal consumption and transfers to related firms must be valued at fair market value and purchases from related firms must be at cost. Provide data for your three most recently completed fiscal years in chronological order from left to right, and for the specified interim periods.

(Quantity in short tons, value in \$1,000)					
Item	Fiscal years ended--			January-June	
	_____	_____	_____	2002	2003
Net sales quantities:²					
Commercial sales					
Internal consumption					
Transfers to related firms					
Total net sales quantities					
Net sales values:²					
Commercial sales					
Internal consumption					
Transfers to related firms					
Total net sales values					
Cost of goods sold (including internal consumption and transfers to related firms):					
Raw materials					
Direct labor					
Other factory costs					
Total cost of goods sold					
Gross profit or (loss)					
Selling, general, and administrative (SG&A) expenses:					
Selling expenses					
General and administrative expenses					
Total SG&A expenses					
Operating income or (loss)					
Other income and expenses:					
Interest expense					
All other expense items					
Continued Dumping and Subsidy Offset Act funds received ³					
All other income items					
All other income or expenses, net					
Net income or (loss) before income taxes					
Depreciation/amortization included above					

¹ Include only sales (whether domestic or export) and costs related to your U.S. manufacturing operations.

² Less discounts, returns, allowances, and prepaid freight. The quantities and values should approximate the corresponding shipment quantities and values reported in Part II of this questionnaire.

³ You must report funds received under this Act in this line. Please reclassify these funds from your records accordingly.

PART III.--FINANCIAL INFORMATION--Continued

- III-7. Capital expenditures, research and development expenditures, and asset values.--Report your firm's capital expenditures and research and development expenditures on EMD, and the values of the property, plant, and equipment used in the production of EMD. Provide data for your three most recently completed fiscal years in chronological order from left to right, and for the specified interim periods.

(Value in \$1,000)					
Item	Fiscal years ended--			January-June	
	_____	_____	_____	2002	2003
Capital expenditures					
Research and development expenditures					
Property, plant, and equipment:					
Original cost					
Book value					

- III-8. Since January 1, 2000, has your firm experienced any actual negative effects on its return on investment or its growth, investment, ability to raise capital, existing development and production efforts (including efforts to develop a derivative or more advanced version of the product), or the scale of capital investments as a result of imports of EMD from Australia, China, Greece, Ireland, Japan, or South Africa?

☐ No

☐ Yes--My firm has experienced actual negative effects as follows:

Cancellation or rejection of expansion projects ☐

Denial or rejection of investment proposal ☐

Reduction in the size of capital investments ☐

Rejection of bank loans ☐

Lowering of credit rating ☐

Problem related to the issue of stocks or bonds ☐

Other (specify) _____

- III-9. Does your firm anticipate any negative impact of imports of EMD from Australia, China, Greece, Ireland, Japan, or South Africa?

☐ No

☐ Yes--My firm anticipates negative effects as follows:

PART IV.--PRICING AND RELATED INFORMATION

Further information on this part of the questionnaire can be obtained from John N. Giamalva (202-205-2785).

IV-1. Who should be contacted regarding the requested pricing and related information?

Company contact: _____
Name and title

Phone No.

E-mail address

Section IV-A.--PRICE DATA

This section requests quarterly price and quantity data concerning your firm's U.S. commercial shipments to unrelated U.S. customers of the following products during January 2000-March 2003:

Product 1.—Standard alkaline grade electrolytic manganese dioxide in powder form

Product 2.—Lithium grade electrolytic manganese dioxide in powder form

Reported values should be f.o.b. your production or storage facility, net of returns, refunds, discounts, and credits, and should be arms-length sales to unrelated U.S. customers.

PART IV.--PRICING AND RELATED INFORMATION--Continued**Section IV-A.--PRICE DATA--Continued**

COPY THIS PAGE AS NECESSARY. Complete a separate page for each of the specified products¹ produced and sold by your firm.

Product 1 ☐ Product 2 ☐

(Quantity in pounds, value in dollars)		
Period of shipment	Quantity	Value ²
2000:		
January-March		
April-June		
July-September		
October-December		
2001:		
January-March		
April-June		
July-September		
October-December		
2002:		
January-March		
April-June		
July-September		
October-December		
2003:		
January-March		
April-June		
¹ If your product does not exactly meet the product specifications but is competitive with the specified product, provide a description of your product: <hr/> <hr/>		
² Net values (i.e., gross sales values less all discounts, allowances, rebates, prepaid freight, and the value of returned goods), f.o.b. your U.S. point of shipment.		

PART IV.--PRICING AND RELATED INFORMATION--Continued

Section IV-B.--BID INFORMATION

Report, as indicated below, information for all bids initiated by your firm for EMD that was to be delivered or scheduled to be delivered during 2000 or later. Include all bids submitted whether or not your firm won the bid, reporting separately for each project. Please photocopy this page as necessary.

Customer name and location	
Type (alkaline grade, lithium grade, zinc-chloride grade, etc.)	
Status of bid	
Initial bid: Date	
Total value of bid (\$1,000)	
Total quantity involved (short tons)	
Product specifications ¹	
Competitors (Firm name and country)	
Final bid: Date	
Total value of bid (\$1,000)	
Total quantity involved (short tons)	
Product specifications ¹	
Competitors (Firm name and country)	
Contract (if won):	
Date	
Total value of contract (\$1,000)	
Total quantity involved (short tons)	
Product specifications ¹	
Delivery date(s)	
Expected completion date	
¹ If multiple product specifications are involved, please attach a list of product specifications.	

Section IV-C.--PRICE-RELATED QUESTIONS

- IV-C-1. Please describe how your firm determines the prices that it charges for sales of EMD (transaction by transaction negotiation, contracts for multiple shipments, set price lists, etc.). If your firm issues price lists, please include a copy of a recent price list with your submission. If your price list is large, please submit sample pages.

- IV-C-2. Please describe your firm's discount policy (quantity discounts, annual total volume discounts, etc.). If your firm has a global discount or rebate program that extends discounts/rebates to companies that purchase EMD in multiple markets, please include a description of this program.

- IV-C-3. What are your firm's typical sales terms for its U.S.-produced EMD (e.g., 2/10 net 30 days)? _____ On what basis are your prices of domestic EMD usually quoted (e.g., f.o.b. warehouse, or delivered)? _____

- III-C-4. Approximately what share of your firm's sales of its U.S. produced EMD in 2002 were on a (1) long-term contract basis (multiple deliveries for more than 12 months after the purchases agreement), (2) short-term contract basis (multiple deliveries up to 12 months), and (3) spot sales basis (for a single delivery)?

Type of sale:	Share of sales (percent)
Long-term contracts	
Short-term contracts	
Spot sales	

PART IV.--PRICING AND RELATED INFORMATION--Continued

Section IV-C.--PRICE-RELATED QUESTIONS--Continued

IV-C-5. If you sell on a long-term contract basis, please answer the following questions with respect to provisions of a typical long-term contract.

(a) What is the average duration of a contract? _____

(b) Can prices be renegotiated with the contract period? _____

(c) Does the contract fix quantity, price, or both? _____

(d) Does the contract have a meet or release provision? _____

IV-C-6. If you sell on a short-term contract basis, please answer the following questions with respect to provisions of a typical short-term contract.

(a) What is the average duration of a contract? _____

(b) Can prices be renegotiated with the contract period? _____

(c) Does the contract fix quantity, price, or both? _____

(d) Does the contract have a meet or release provision? _____

IV-C-7. What is the average lead time between a customer's order and the date of delivery for your firm's sales of your U.S.-produced PRODUCT?

Source	Share of 2001 sales	Lead time
From inventory		
Produced to order		
Total	100%	(average)

IV-C-8. What is the approximate percentage of the total delivered cost of EMD that is accounted for by U.S. inland transportation costs? ____ percent. Who generally arranges the transportation to your customers' locations? Your firm ____ or purchaser ____ (check one). What proportion of your sales occur within 100 miles of your storage or production facility? ____ percent. 101 to 1,000 miles? ____ percent. Over 1,000 miles? ____ percent.

PART IV.--PRICING AND RELATED INFORMATION--Continued

Section IV-C.--PRICE-RELATED QUESTIONS--Continued

IV-C-9. What is the geographic market area in the United States served by your firm's EMD?

IV-C-10. What other products may be substitutes for EMD?

IV-C-11. Describe the end uses of the EMD that you manufacture. For each end use product, what percentage of the total cost is accounted for by EMD?

IV-C-12. How has the demand within the United States (and outside the United States if known) for EMD changed since January 1, 2000? What were the principal factors affecting changes in demand?

IV-C-13. Have there been any significant changes in the product range or marketing of EMD in the past five years?

☐ No ☐ Yes--Please describe.

IV-C-14. Does your firm sell EMD over the internet?

☐ No ☐ Yes--Please describe, noting the estimated percentage of your firm's total sales of EMD in 2002 accounted for by internet sales.

PART IV.--PRICING AND RELATED INFORMATION--Continued**Section IV-C.--PRICE-RELATED QUESTIONS--Continued**

IV-C-15. Is EMD produced in the United States and in other countries used interchangeably (i.e., can they physically be used in the same applications)? Please indicate below, using "A" to indicate that the products from a specified country-pair are *always* interchangeable, "F" to indicate that the products are *frequently* interchangeable, "S" to indicate that the products are *sometimes* interchangeable, "N" to indicate that the products are *never* interchangeable, and "0" to indicate *no familiarity* with products from a specified country-pair.¹

Country-pair	United States	Australia	China	Greece	Ireland	Japan	South Africa	Other countries
United States								
Australia								
China								
Greece								
Ireland								
Japan								
South Africa								

¹ For any country-pair producing EMD which is *sometimes* or *never* used interchangeably, please explain the factors that limit or preclude interchangeable use:

Section IV-C.—PRICE-RELATED QUESTIONS—Continued

IV-C-16. Are differences other than price (i.e., quality, availability, transportation network, product range, technical support, etc.) between EMD produced in the United States and in other countries a significant factor in your firm's sales of the products? Please indicate below, using "A" to indicate that such differences are *always* significant, "F" to indicate that such differences are *frequently* significant, "S" to indicate that such differences are *sometimes* significant, "N" to indicate that such differences are *never* significant, and "0" to indicate *no familiarity* with products from a specified country-pair.¹

Country-pair	United States	Australia	China	Greece	Ireland	Japan	South Africa	Other countries
United States								
Australia								
China								
Greece								
Ireland								
Japan								
South Africa								

¹ For any country-pair for which factors other than price *always or frequently* are a significant factor in your firm's sales of EMD, identify the country-pair and report the advantages or disadvantages imparted by such factors:

PART IV.--PRICING AND RELATED INFORMATION--Continued

Section IV-D.--CUSTOMER IDENTIFICATION

Please identify below the names and addresses of your firm's 10 largest customers for EMD during 2000-2002. Please also provide the name and telephone number of a contact person and the share of the quantity of your firm's total shipments of EMD that each of these customers accounted for in 2002.

No.	Customer's name	Street address (not P.O. box), state, and zip code	Contact person	Area code and telephone number	Share of 2002 sales (%)
1					
2					
3					
4					
5					
6					
7					
8					
9					
10					

PART IV.--PRICING AND RELATED INFORMATION--Continued**Section IV-E.--COMPETITION FROM IMPORTS--LOST REVENUES**

Instructions for preliminary investigation: **THIS SECTION IS TO BE COMPLETED ONLY BY NON-PETITIONERS.** (Note: petitioners may provide allegations involving quotes made AFTER the filing of the petition.)

Instructions for final investigation: **PLEASE DO NOT RE-SUBMIT ALLEGATIONS PROVIDED IN THE PRELIMINARY PHASE OF THESE INVESTIGATIONS.**

Since January 1, 2000: To avoid losing sales to competitors selling EMD from Australia, China, Greece, Ireland, Japan, or South Africa, did your firm:

Reduce prices ☐ Yes ☐ No

Roll back announced price increases ☐ Yes ☐ No

If yes, please furnish as much of the following information as possible for each affected transaction. Document such allegations of lost revenues whenever possible (documentation could include copies of invoices, sales reports, or letters from customers). **Please note that the Commission may contact the firms named to verify the allegations reported.**

Customer name, contact person, phone and fax numbers

Specific product(s) involved

Date of your initial price quotation

Quantity involved

Your initial *rejected* price quotation (total delivered value)

Your *accepted* price quotation (total delivered value)

The country of origin of the competing imported product

The competing price quotation of the imported product (total delivered value)

Customer name, contact person, phone and fax numbers	Product	Date of quote	Quantity (short tons)	Initial rejected U.S. price (total value--dollars)	Accepted U.S. price (total value--dollars)	Country of origin	Competing import price (total value--dollars)

PART IV.--PRICING AND RELATED INFORMATION--Continued

Section IV-F.--COMPETITION FROM IMPORTS--LOST SALES

Instructions for preliminary investigation: **THIS SECTION IS TO BE COMPLETED ONLY BY NON-PETITIONERS.** (Note: petitioners may provide allegations involving quotes made AFTER the filing of the petition.)

Instructions for final investigation: **PLEASE DO NOT RE-SUBMIT ALLEGATIONS PROVIDED IN THE PRELIMINARY PHASE OF THESE INVESTIGATIONS.**

Since January 1, 2000: Did your firm lose sales of EMD to imports of these products from Australia, China, Greece, Ireland, Japan, or South Africa?

☐ Yes

☐ No

If yes, please furnish as much of the following information as possible for each affected transaction. Document such allegations of lost sales whenever possible (documentation could include copies of invoices, sales reports, or letters from customers). **Please note that the Commission may contact the firms named to verify the allegations reported.**

Customer name, contact person, phone and fax numbers

Specific product(s) involved

Date of your price quotation

Quantity involved

Your rejected price quotation (total delivered value)

The country of origin of the competing imported product

The accepted price quotation of the imported product (total delivered value)

Customer name, contact person, phone and fax numbers	Product	Date of quote	Quantity (<i>short tons</i>)	Rejected U.S. price (total value-- dollars)	Country of origin	Accepted import price (total value-- dollars)